Apellis Pharmaceuticals Inc. APLS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its key products include EMPAVELI, approved for paroxysmal nocturnal hemogl…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees733
TickerAPLS
Statistics
Market Cap$449.6M
Revenue (TTM)$94.6M
Net Income—
Net Margin—
EPS—
P/E38.35
P/S4.75
P/B12.65
EV/EBITDA31.94
ROE46.0%
Dividend Yield—
Price$3.52
Data: Twelve Data · Revenue = mcap / P/S